Fundamental Analysis of VIKING THERAPEUTICS INC(NASDAQ:VKTX) stock

Fundamental Rating

VKTX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for VKTX as it has an excellent financial health rating, but there are worries on the profitability. VKTX has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year VKTX has reported negative net income.

In the past year VKTX has reported a negative cash flow from operations.

In the past 5 years VKTX always reported negative net income.

VKTX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a decent Return On Assets value of -9.69%, VKTX is doing good in the industry, outperforming 78.42% of the companies in the same industry.

VKTX's Return On Equity of -10.04% is amongst the best of the industry. VKTX outperforms 84.25% of its industry peers.

		Industry Rank	Sector Rank
ROA	-9.69%
ROE	-10.04%
ROIC	N/A

ROA(3y)-30.09%

ROA(5y)-22.95%

ROE(3y)-33.1%

ROE(5y)-24.95%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

VKTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

VKTX has more shares outstanding than it did 1 year ago.

The number of shares outstanding for VKTX has been increased compared to 5 years ago.

VKTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

VKTX has an Altman-Z score of 146.33. This indicates that VKTX is financially healthy and has little risk of bankruptcy at the moment.

With an excellent Altman-Z score value of 146.33, VKTX belongs to the best of the industry, outperforming 99.66% of the companies in the same industry.

There is no outstanding debt for VKTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	146.33

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 29.48 indicates that VKTX has no problem at all paying its short term obligations.

VKTX has a Current ratio of 29.48. This is amongst the best in the industry. VKTX outperforms 94.86% of its industry peers.

A Quick Ratio of 29.48 indicates that VKTX has no problem at all paying its short term obligations.

VKTX has a better Quick ratio (29.48) than 94.86% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	29.48
Quick Ratio	29.48

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

VKTX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.11%.

EPS 1Y (TTM)2.11%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-4%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

VKTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.62% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-24.58%

EPS Next 2Y-29.69%

EPS Next 3Y-18.61%

EPS Next 5Y23.62%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VKTX. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VKTX. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

VKTX's earnings are expected to decrease with -18.61% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-29.69%

EPS Next 3Y-18.61%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

VKTX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

VIKING THERAPEUTICS INC

NASDAQ:VKTX (4/26/2024, 7:22:45 PM)

After market: 74.4 +0.09 (+0.12%)

74.31

+5.45 (+7.91%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap8.19B

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-9.69%
ROE	-10.04%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	29.48
Quick Ratio	29.48
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)2.11%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-24.58%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

VIKING THERAPEUTICS INC (VKTX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens